HPV integration as a prognostic biomarker for metastatic anal cancer: A next-generation sequencing ctDNA-based approach. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...

Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a ...

– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) “Petosemtamab’s unique mechanism of ...

Phase 1b study to assess the safety of neoadjuvant trifluridine/tipiracil with concurrent radiation in resectable stage II/III rectal cancer. This is an ASCO Meeting Abstract from the 2023 ASCO ...

PLYMOUTH MEETING, PA [September 5, 2024] — New research just-published online by JNCCN—Journal of the National Comprehensive Cancer Network finds that for many commonly used treatment regimens ...

- Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile UTRECHT, The Netherlands and ...

Yakult Honsha has patented a method for predicting the effectiveness of FOLFOX or FOLFIRI regimens in treating stage IV colorectal cancer. By measuring copy number gains in specific chromosome regions ...

SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated ...